Edition:
United Kingdom

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

6.09EUR
4:35pm BST
Change (% chg)

€-0.17 (-2.79%)
Prev Close
€6.27
Open
€6.22
Day's High
€6.22
Day's Low
€6.01
Volume
254,764
Avg. Vol
306,820
52-wk High
€12.89
52-wk Low
€4.33

Latest Key Developments (Source: Significant Developments)

Innate Pharma FY Net Results Swings To Loss Of 48.4‍​ Million Euros
Thursday, 8 Mar 2018 

March 8 (Reuters) - INNATE PHARMA SA ::FY REVENUE AND OTHER INCOME EUR 44.0‍​ MILLION VERSUS EUR 65.7 MILLION YEAR AGO.FY OPERATING LOSS EUR 40.0‍​ MILLION VERSUS INCOME EUR 7.6 MILLION YEAR AGO.FY NET LOSS EUR 48.4‍​ MILLION VERSUS INCOME EUR 12.6 MILLION YEAR AGO.CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS AMOUNTED TO EUR 176.6 MILLION AS OF DEC. 31.IPH5401 WILL ENTER FIRST CLINICAL STUDIES IN ONCOLOGY IN 2018.EXPECTS CLINICAL READ-OUTS FOR BOTH MONALIZUMAB AND IPH4102 PROGRAM IN 2018.  Full Article

Eric Vivier Joins Innate Pharma As Chief Scientific Officer
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Innate Pharma Sa ::REG-WORLD RENOWNED IMMUNOLOGIST, PROFESSOR ERIC VIVIER, JOINS INNATE PHARMA AS CHIEF SCIENTIFIC OFFICER.  Full Article

Innate Pharma provides an update on lirilumab
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - INNATE PHARMA SA ::REG-INNATE PHARMA PROVIDES AN UPDATE ON LIRILUMAB.‍LIRILUMAB CONTINUES TO BE WELL-TOLERATED IN MONOTHERAPY AND IN COMBINATION ACROSS MULTIPLE TUMOR INDICATIONS.COMBINATION OF NIVOLUMAB PLUS LIRILUMAB IN EXTENDED POPULATION OF PATIENTS WITH SCCHN DID NOT PROVIDE CLEAR EVIDENCE OF BENEFIT TO PATIENTS OR OBVIOUS DEVELOPMENT PATH.‍‍ON COMBINATION OF NIVOLUMAB PLUS LIRILUMAB: DISCUSSIONS ARE ONGOING REGARDING NEXT STEPS.AN UPDATE IS PLANNED FOR EARLY 2018​.  Full Article

Innate Pharma Q3 revenue up at 12.4 million euros
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - INNATE PHARMA SA ::Q3 REVENUE EUR 12.4 MILLION VERSUS EUR 11.2 MILLION YEAR AGO.9 MONTH REVENUE EUR 27.9 MILLION VERSUS EUR 27.9 MILLION YEAR AGO.CASH POSITION AT SEPT 30 EUR 195.7 MILLION VERSUS EUR 239.6 MILLION YEAR AGO.  Full Article

Innate Pharma issues 3,343,748 ordinary shares
Thursday, 13 Jul 2017 

July 13 (Reuters) - INNATE PHARMA SA ::REG-ISSUANCE BY INNATE PHARMA OF 3,343,748 ORDINARY SHARES TO NOVO NORDISK A/S IN CONSIDERATION FOR RIGHTS IN ANTI-C5AR.ACQUISITION OF ANTI-C5AR, A FIRST-IN-CLASS CLINICAL-STAGE ANTIBODY, ANNOUNCED ON JUNE 2, 2017, IS NOW FINALIZED;.NOVO NORDISK A/S'S STAKE IN SHARE CAPITAL OF INNATE PHARMA INCREASES FROM 10.3% TO 15.5%.TERMS OF AGREEMENT PROVIDE FOR UPFRONT PAYMENT OF EUR 40MLN, OF WHICH EUR 37.2MLN WILL BE PAID IN FORM OF NEW SHARES IN COMPANY AND EUR 2.8M WILL BE PAID IN CASH.UNDER THE TRANSACTION, INNATE PHARMA DOES ACQUIRE WORLDWIDE RIGHTS TO ANTI-C5AR/IPH5401 IN ALL INDICATIONS FROM NOVO.  Full Article

Innate Pharma to list 3,343,748 new ordinary shares - Euronext‍​
Thursday, 13 Jul 2017 

July 13 (Reuters) - EURONEXT::INNATE PHARMA <<>> TO LIST 3,343,748 NEW ORDINARY SHARES AS OF JULY 17 FOLLOWING CAPITAL INCREASE BY CONTRIBUTION.  Full Article

Innate Pharma acquires anti-c5ar from Novo Nordisk A/S
Friday, 2 Jun 2017 

June 2 (Reuters) - Innate Pharma Sa ::Innate Pharma acquires anti-c5ar, a first-in-class clinical-stage antibody, from Novo Nordisk A/S.Innate Pharma SA - ‍terms of transaction provide for a total upfront payment of EUR 40 million​.Innate Pharma SA- innate pharma intends to start clinical trials with anti-c5ar (iph5401) in oncology in 2018.Innate Pharma SA- acquisition is part of a transaction in which Novo Nordisk A/S will increase its equity stake in Innate Pharma.Innate Pharma SA - ‍total upfront payment of eur 40 million, consists of eur 37.2m to be paid in new innate pharma shares and eur 2.8 million in cash​.Innate Pharma - after issuance of new shares, stake of Novo Nordisk A/S in innate pharma will increase from 10.3% to between 14.6 pct to 15.8 pct.Innate Pharma SA - ‍novo Nordisk A/S will also be eligible for double digit royalties on net sales​.Innate Pharma - ‍novo Nordisk A/S will be eligible for eur 370 million in development, regulatory and sales milestone payments​.  Full Article

Innate Pharma acquires anti-C5aR from Novo Nordisk
Friday, 2 Jun 2017 

June 2 (Reuters) - Innate Pharma Sa :Innate Pharma acquires anti-C5aR, a first-in-class clinical-stage antibody, from Novo Nordisk A/S.Says Innate Pharma intends to start clinical trials with anti-C5aR (iph5401) in oncology in 2018.Says acquisition is part of a transaction in which Novo Nordisk A/S will increase its equity stake in Innate Pharma.Innate Pharma - terms provide for a total upfront payment of EUR 40M, of which EUR 37.2M will be paid in new Innate Pharma shares and EUR 2.8M in cash.Says Novo Nordisk A/S will be eligible for EUR 370M in development, regulatory and sales milestone payments.Says Novo Nordisk A/S will also be eligible for double digit royalties on net sales..  Full Article

Innate Pharma Q1 revenue up at EUR 7.3 mln
Monday, 15 May 2017 

May 15 (Reuters) - INNATE PHARMA SA :Q1 REVENUE EUR ‍​7.3 MLN VS EUR 5.7 MLN YR AGO.CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS AT MARCH 31 AMOUNT TO EUR 223.8 MLN.INNATE PHARMA SA IPH.PA CEO SAYS "WE ARE WELL PLACED TO DELIVER SHAREHOLDER VALUE AND IMPROVED TREATMENT OPTIONS TO PATIENTS".  Full Article

Innate Pharma FY operating profit down at 7.6 million euros
Tuesday, 7 Mar 2017 

Innate Pharma SA : Cash and cash equivalents at December 31, 2016 230.7 million euros ($244.47 million) versus 273.7 million euros year ago . FY net profit of 12.6 million euros versus loss of 6.7 million euros year ago . FY operating profit of 7.6 million euros versus loss of 10.8 million euros year ago .FY revenue 65.7 million euros versus 25.1 million euros year ago.  Full Article

French and Benelux stocks-Factors to watch on April 18

April 18 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.